TOT BIOPHARM International Company Limited reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 182.02 million compared to CNY 23.13 million a year ago. Net loss was CNY 15.72 million compared to CNY 115.01 million a year ago.

Basic loss per share from continuing operations was CNY 0.03 compared to CNY 0.2 a year ago.